AR032353A1 - Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene - Google Patents
Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contieneInfo
- Publication number
- AR032353A1 AR032353A1 ARP010102936A ARP010102936A AR032353A1 AR 032353 A1 AR032353 A1 AR 032353A1 AR P010102936 A ARP010102936 A AR P010102936A AR P010102936 A ARP010102936 A AR P010102936A AR 032353 A1 AR032353 A1 AR 032353A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr1r2
- integer
- heterocyclic
- alkyl
- atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 17
- 125000004429 atom Chemical group 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- -1 -NR1R2 Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21313600P | 2000-06-22 | 2000-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032353A1 true AR032353A1 (es) | 2003-11-05 |
Family
ID=22793862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102936A AR032353A1 (es) | 2000-06-22 | 2001-06-20 | Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene |
Country Status (42)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| JP2002526538A (ja) | 1998-10-01 | 2002-08-20 | アストラゼネカ アクチボラグ | 化学化合物 |
| BR0111548A (pt) * | 2000-06-22 | 2003-05-06 | Pfizer Prod Inc | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal |
| WO2002066445A1 (en) * | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
| US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
| IL160971A0 (en) * | 2001-11-30 | 2004-08-31 | Pfizer Prod Inc | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| CN1602195A (zh) * | 2001-12-12 | 2005-03-30 | 辉瑞产品公司 | 用于治疗异常细胞生长的喹唑啉衍生物 |
| HUP0402662A2 (hu) | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| WO2004006846A2 (en) | 2002-07-15 | 2004-01-22 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| WO2004046101A2 (en) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| MXPA05006335A (es) * | 2002-12-18 | 2005-08-26 | Pfizer Prod Inc | Derivados biciclicos para el tratamiento del crecimiento celular anormal. |
| PL377533A1 (pl) * | 2002-12-19 | 2006-02-06 | Pfizer Products Inc. | Kompleksy E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylopirydyn-3-yloksy)-fenyloamino]-chinazolin-6-ylo}-allilo)-acetamidu, sposób ich wytwarzania i zastosowanie |
| RU2005125607A (ru) * | 2003-04-09 | 2006-03-27 | Пфайзер Продактс Инк. (Us) | Способы получения производных n(пиридинилокси)-фениламино)хиназолинил)аллил)ацетамида и родственных соединений, а также промежуточные соединения для таких способов и способы получения таких соединений |
| BRPI0410720A (pt) * | 2003-05-27 | 2006-06-20 | Pfizer Prod Inc | quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase |
| CN1984660B (zh) | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| JP2007533596A (ja) * | 2003-07-15 | 2007-11-22 | ナショナル・リサーチ・カウンシル・オブ・カナダ | 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| WO2005016347A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| ATE395346T1 (de) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| WO2005044302A1 (en) * | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ES2315834T3 (es) | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| JPWO2006025490A1 (ja) * | 2004-09-01 | 2008-05-08 | 田辺三菱製薬株式会社 | 分子シャペロン機能調節剤 |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2763671A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| CA2610661A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| CN101517068B (zh) | 2005-09-07 | 2017-02-08 | 安进弗里蒙特公司 | 活化素受体样激酶‑1的人单克隆抗体 |
| DK1971601T3 (da) | 2005-11-15 | 2010-02-08 | Array Biopharma Inc | N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme |
| GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| BRPI0711358A2 (pt) | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | derivados do ácido cicloalquilamino e suas composições farmacêuticas |
| WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
| MX2009002585A (es) * | 2006-09-11 | 2009-08-24 | Curis Inc | Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc. |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JPWO2008072634A1 (ja) | 2006-12-12 | 2010-04-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EA200901041A1 (ru) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения |
| US8715665B2 (en) | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
| PL2245026T3 (pl) | 2008-02-07 | 2013-01-31 | Boehringer Ingelheim Int | Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji |
| EP2253633A4 (en) | 2008-03-12 | 2012-02-29 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| EP2630134B9 (en) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
| PE20141228A1 (es) | 2011-09-22 | 2014-10-01 | Pfizer | Derivados de pirrolopirimidina y purina |
| CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| CR20160497A (es) | 2014-04-30 | 2016-12-20 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| EP3424928A4 (en) * | 2016-03-01 | 2019-10-09 | Shanghai Pharmaceuticals Holding Co., Ltd. | NITROGENIC HETEROCYCLIC COMPOUND, MANUFACTURING METHOD, INTERMEDIATE PRODUCT, COMPOSITION AND USE |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| RS66314B1 (sr) | 2018-09-18 | 2025-01-31 | Hoffmann La Roche | Derivati hinazolina kao antitumorski agensi |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
| WO2025067396A1 (zh) * | 2023-09-27 | 2025-04-03 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| ATE294796T1 (de) | 1998-10-08 | 2005-05-15 | Astrazeneca Ab | Chinazolin derivate |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| BR0111548A (pt) * | 2000-06-22 | 2003-05-06 | Pfizer Prod Inc | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal |
-
2001
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active Expired - Fee Related
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en not_active Ceased
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166D0/no unknown
-
2005
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032353A1 (es) | Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene | |
| AR046926A1 (es) | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer | |
| AR077553A2 (es) | Compuestos de triazolo [4,5-d] pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacion de dichos compuestos | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| AR011174A1 (es) | Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
| AR013086A1 (es) | Compuestos derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4 sustituidos, composiciones que los contienen, metodos para preparar los compuestos, uso de dichos compuestos e intermediarios para su preparacion | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| AR013085A1 (es) | Compuestos derivados de macrolidos c-4'' sustituidos, composicion farmaceutica, metodo de preparacion, compuestos intermediarios para su preparacion | |
| AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| AR034284A1 (es) | Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central | |
| AR071592A1 (es) | Fenoxibenzamidas sustituidas | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR037591A1 (es) | Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y compuestos utiles en dichos procedimientos | |
| EP0385722A3 (en) | Tricyclic lactam derivatives and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |